Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages 6512-6517

  Kueffer, Peter J ^a   Maitz, Charles A ^a   Khan, Aslam A ^a   Schuster, Seth A ^a   Shlyakhtina, Natalia I ^a   Jalisatgi, Satish S ^a   Brockman, John D ^a   Nigg, David W ^a,b   Hawthorne, M Frederick ^a  

^a University of Missouri   (United States)

^b IDAHO NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; CHOLESTEROL; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; LIPOSOMAL DELIVERY; MOUSE; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; BORANES; BORON NEUTRON CAPTURE THERAPY; FEMALE; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHATIDYLCHOLINES; TIME FACTORS; TREATMENT OUTCOME;

MUS;

EID: 84876225948     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1303437110     Document Type: Article

References (44)

1. Coderre JA, Morris GM (1999) The radiation biology of boron neutron capture therapy. Radiat Res 151(1):1-18.
2. Hopewell JW, Morris GM, Schwint A, Coderre JA (2011) The radiobiological principles of boron neutron capture therapy: A critical review. Appl Radiat Isot 69(12):1756-1759.
3. Sweet WH (1997) Early history of development of boron neutron capture therapy of tumors. J Neurooncol 33(1-2):19-26.
4. Valliant J, et al. (2002) The medicinal chemistry of carboranes. Coord Chem Rev 232 (1-2):173-230.
5. Soloway AH, et al. (1998) The chemistry of neutron capture therapy. Chem Rev 98(4): 1515-1562.
6. Hawthorne M (1993) The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed Engl 32(7):950-984.
7. Hawthorne MF (1998) New horizons for therapy based on the boron neutron capture reaction. Mol Med Today 4(4):174-181.
8. Busse PM, et al. (2003) A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 62(1-2):111-121.
9. Diaz AZ (2003) Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 62(1-2):101-109.
10. Barth RF, Coderre JA, Vicente MG, Blue TE (2005) Boron neutron capture therapy of cancer: Current status and future prospects. Clin Cancer Res 11(11):3987-4002.
11. Henriksson R, et al.; Swedish Brain Tumour Study Group (2008) Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 88(2): 183-191.
12. Hopewell JW, et al. (2011) Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential. Appl Radiat Isot 69(12): 1737-1740.
13. Nakai K, et al. (2011) Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: A recursive partitioning analysis of BNCT patients. Appl Radiat Isot 69(12):1790-1792.
14. Kankaanranta L, et al. (2012) Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: Final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys 82(1):e67-e75.
15. Hawthorne M, Lee M (2003) A critical assessment of boron target compounds for boron neutron capture therapy. J Neurooncol 62(1-2):33-45.
16. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 pt 1):6387-6392.
17. Fang J, Nakamura H, Maeda H (2011) The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63(3):136-151.
18. Shelly K, et al. (1992) Model studies directed toward the boron neutron-capture therapy of cancer: Boron delivery to murine tumors with liposomes. Proc Natl Acad Sci USA 89(19):9039-9043.
19. Hawthorne MF, Shelly K (1997) Liposomes as drug delivery vehicles for boron agents. J Neurooncol 33(1-2):53-58.
20. 2-. Inorg Chem 3(3):444-451.
21. 3]: Synthesis and liposomal delivery to murine tumors. Proc Natl Acad Sci USA 91(8):3029-3033.
22. 4. Inorg Chem 35(19):5412-5416.
23. 8] as a potential agent for boron neutron capture therapy. Proc Natl Acad Sci USA 96(11):6406-6410.
24. McVey WJ, et al. (2008) Investigation of the interactions of polyhedral borane anions with serum albumins. J Inorg Biochem 102(4):943-951.
25. 3] and their structural characterization. Inorg Chem 38(22):4926-4927.
26. -. Angew Chem Int Ed Engl 37(13-14):1868-1871.
27. 2- ions: Novel reactions and structural motifs. Chem Commun (Camb) 38(6):547-554.
28. Irani K, et al. (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275(5306):1649-1652.
29. Oberley TD (2002) Oxidative damage and cancer. Am J Pathol 160(2):403-408.
30. Feakes DA, Shelly K, Hawthorne MF (1995) Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci USA 92(5):1367-1370.
31. Straubinger RM, Hong K, Friend DS, Papahadjopoulos D (1983) Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles. Cell 32(4):1069-1079.
32. Straubinger RM, Papahadjopoulos D, Hong KL (1990) Endocytosis and intracellular fate of liposomes using pyranine as a probe. Biochemistry 29(20):4929-4939.
33. Lee KD, Nir S, Papahadjopoulos D (1993) Quantitative analysis of liposome-cell interactions in vitro: Rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 32(3):889-899.
34. Khalil I, Kogure K, Akita H, Harashima H (2006) Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 58:32-45.
35. Heber EM, et al. (2012) Boron delivery with liposomes for boron neutron capture therapy (BNCT): Biodistribution studies in an experimental model of oral cancer demonstrating therapeutic potential. Radiat Environ Biophys 51(2):195-204.
36. Brockman J, Nigg DW, Hawthorne MF, McKibben C (2009) Spectral performance of a composite single-crystal filtered thermal neutron beam for BNCT research at the University of Missouri. Appl Radiat Isot 67(7-8, suppl):(suppl):S222- S225.
37. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457-481.
38. Miura M, et al. (2001) Boron neutron capture therapy of a murine mammary carcinoma using a lipophilic carboranyltetraphenylporphyrin. Radiat Res 155(4):603-610.
39. 10B-L-borophenylalanine for boron neutron capture therapy. Br J Radiol 71(843):320-323.
40. Ono K, et al. (1996) Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: Its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys 34(5): 1081-1086.
41. Twentyman PR, Bleehen NM (1976) The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour. Br J Cancer 33(3):320-328.
42. Kwok TT, Twentyman PR (1985) The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroids. Br J Cancer 51(2):211-218.
43. Kreimann EL, et al. (2001) The hamster cheek pouch as a model of oral cancer for boron neutron capture therapy studies: Selective delivery of boron by bor-onophenylalanine. Cancer Res 61(24):8775-8781.
44. Sun D-H, Waters J, Mawhinney T (1997) Microwave digestion and ultrasonic nebuli-zation for determination of boron in animal tissues by inductively coupled plasma atomic emission spectrometry with internal standardization and addition of manni-tol. J Anal At Spectrom 12(6):675-679.